Lewy Body Dementia Association\u27s Research Centers of Excellence Program: Inaugural Meeting Proceedings.

The first Lewy Body Dementia Association (LBDA) Research Centers of Excellence (RCOE) Investigator\u27s meeting was held on December 14, 2017, in New Orleans. The program was established to increase patient access to clinical experts on Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson\u27s disease dementia (PDD), and to create a clinical trials-ready network. Four working groups (WG) were created to pursue the LBDA RCOE aims: (1) increase access to high-quality clinical care, (2) increase access to support for people living with LBD and their caregivers, (3) increase knowledge of LBD among medical and allied (or other) professionals, and (4) create infrastructure for a clinical trials-ready network as well as resources to advance the study of new therapeutics

Lewy Body Dementia Association’s Research Centers of Excellence Program: Inaugural Meeting Proceedings

Abstract The first Lewy Body Dementia Association (LBDA) Research Centers of Excellence (RCOE) Investigator’s meeting was held on December 14, 2017, in New Orleans. The program was established to increase patient access to clinical experts on Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), and to create a clinical trials-ready network. Four working groups (WG) were created to pursue the LBDA RCOE aims: (1) increase access to high-quality clinical care, (2) increase access to support for people living with LBD and their caregivers, (3) increase knowledge of LBD among medical and allied (or other) professionals, and (4) create infrastructure for a clinical trials-ready network as well as resources to advance the study of new therapeutics.https://deepblue.lib.umich.edu/bitstream/2027.42/148286/1/13195_2019_Article_476.pd

Consensus classification of posterior cortical atrophy

INTRODUCTION: A classification framework for posterior cortical atrophy (PCA) is proposed to improve the uniformity of definition of the syndrome in a variety of research settings. METHODS: Consensus statements about PCA were developed through a detailed literature review, the formation of an international multidisciplinary working party which convened on four occasions, and a Web-based quantitative survey regarding symptom frequency and the conceptualization of PCA. RESULTS: A three-level classification framework for PCA is described comprising both syndrome- and disease-level descriptions. Classification level 1 (PCA) defines the core clinical, cognitive, and neuroimaging features and exclusion criteria of the clinico-radiological syndrome. Classification level 2 (PCA-pure, PCA-plus) establishes whether, in addition to the core PCA syndrome, the core features of any other neurodegenerative syndromes are present. Classification level 3 (PCA attributable to AD [PCA-AD], Lewy body disease [PCA-LBD], corticobasal degeneration [PCA-CBD], prion disease [PCA-prion]) provides a more formal determination of the underlying cause of the PCA syndrome, based on available pathophysiological biomarker evidence. The issue of additional syndrome-level descriptors is discussed in relation to the challenges of defining stages of syndrome severity and characterizing phenotypic heterogeneity within the PCA spectrum. DISCUSSION: There was strong agreement regarding the definition of the core clinico-radiological syndrome, meaning that the current consensus statement should be regarded as a refinement, development, and extension of previous single-center PCA criteria rather than any wholesale alteration or redescription of the syndrome. The framework and terminology may facilitate the interpretation of research data across studies, be applicable across a broad range of research scenarios (e.g., behavioral interventions, pharmacological trials), and provide a foundation for future collaborative work

Visuospatial Assessment by Virtual 3D Radial Optic Flow Illusion in Healthy Aging, Mild Alzheimer's Disease (AD) and Pre-Deep-Brain Stimulation (DBS) Parkinson's Disease (PD) Subjects

Optic flow (the pattern of motion at the eye) controls human walking. Perception of the focus of expansion (FOE) of a radially expanding pattern of moving dots (radial optic flow or ROF) is impaired in AD, but has not been investigated in PD. In the ROF illusion (ROFI), the FOE is perceived as shifted in the direction of a superimposed planar motion pattern (similar motion created by pursuit eye movements)

3D Radial Optic Flow Perception in Alzheimer's Disease and Parkinson's Disease With Advanced Motor Symptoms

Optic flow (the pattern of motion at the eye) controls human walking, and the disruption of visually-driven, cognitive neuronal networks involved in radial optic flow (ROF) processing contributes to spatial navigation errors in Alzheimer's disease (AD).1 These data are based on ROF motion stimuli presented in 2D, while 3D ROF stimuli (simulating real-life) have not been investigated in AD and may have different cognitive correlates. The specificity of impaired ROF perception is unknown since it has not been studied in other neurodegenerative diseases. The aim of this study was to compare the perception of 3D ROF patterns in healthy older adults (HOA), AD, and Parkinson's disease subjects with advanced motor symptoms (PD-AMS)

Two Cases of Wolfram-Related Optic Atrophy: A New Mutation and A Misdiagnosis of Normal-tension Glaucoma

The phenotypic spectrum of WFS1-related disorders, spanning from Wolfram syndrome (WFS) to WFS1-related low-frequency hearing loss, are linked to mutations in the WFS1 gene. We describe two patients with WFS1 gene mutations with an incomplete DIDMOAD tetrad and highlight a previously unreported WFS1 mutation in one proband and a misdiagnosis of normal-tension glaucoma (NTG) in the other

OCT and Neurodegeneration of Alzheimer's Disease and Parkinson's Disease (video)

Given that post-mortem human and animal histopathological studies reveal that degeneration of the inner retina occurs in Alzheimer's disease (AD) and Parkinson's disease (PD), optical coherence tomography (OCT) of the retina is being investigated as a potential biomarker for AD and PD. Dramatic changes in our understanding of AD and PD, the two most common and devastating neurodegenerative diseases of aging, have occurred in the last two decades. The major driver of recent advancements is the recognition of the impending health care crisis that will occur mid-century as the population continues to age and no disease-modifying treatments become available for AD and PD.Patient Care, Medical Knowledge, PBLI, SBP, VBnflaopticalcoherencetomography, SPparkinsonsyndrome, SPparkinsondiseas